A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
← catalyst calendarNCT07087795 · readout in 24 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
96estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-01 | actual | When the study began enrolling |
| Primary completion | 2026-09-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Interventions
- Drug: NNC0194-0499
- Drug: Placebo
- Drug: Semaglutide
Primary outcomes
what the primary-completion date above is the date OFPart A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)
measured From baseline (day -14 - -1) to day 36-49 / day 106-119
Part B: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)
measured From baseline (day -14 - -1) to day 92-105 / day 162-175
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed